The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

Chair Lina Khan's description of the agency she oversees. But such an ahistorical description of the FTC is antithetical to ...

opens new tab to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight-loss drug. Last week, U.S. Senator ...

Federal racing regulators took a major step back by voluntarily limiting their use of provisional suspensions against some ...

This story was originally published by KFF Health News. While customers at Adams Family Pharmacy picked up their ...

In a September 25, 2024 editorial, The Wall Street Journal notes that if the FTC is successful, it will result in higher drug costs for American consumers. The Congressional Budget Office (CBO ...

These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers and insurance companies. Last month, the Federal Trade Commission sued three major PBMs — ...

The FTC accuses major PBMs of inflating insulin prices, impacting patient costs and access to affordable medications. PBMs prioritize high-rebate drugs, contributing to high insulin prices and ...